Table 1.

Acute SARS-CoV-2 infected patients show an altered pattern of DC homing and activation markers

Activation markers	Dendritic cells	Acute	HD	p
Beta7	mDCs	5.7 [3.2–11.1]	22.1 [15.7–33.8]	<0.0001
	CD1c+ mDCs	43.8 [26.2–62.2]	62.0 [38.8–69.7]	0.0340
	CD16+ mDCs	0.0 [0.0–0.0]	0.03 [0.00–0.0]	0.0851
	CD141+ mDCs	15.6 [9.9–28.2]	25.9 [18.8–33.3]	0.0547
	pDCs	2.2 [0.5–3.3]	6.1 [3.2–10.4]	0.0004
CCR7	mDCs	3.1 [1.4–21.7]	0.9 [0.3–1.5]	<0.0001
	CD1c+ mDCs	18.2 [6.4–94.3]	4.5 [2.4–8.1]	<0.0001
	CD16+ mDCs	3.1 [0.3–14.4]	0.3 [0.1–0.5]	0.0015
	CD141+ mDCs	11.0 [3.1–18.5]	1.9 [0.6–4.6]	0.0005
	pDCs	0.9 [0.2–15.6]	0.0 [0.0–0.0]	<0.0001
CD86	mDCs	64.9 [37.9–77.4]	57.7 [50.4–65.2]	0.4447
	CD1c+ mDCs	5.5 [2.8–11.2]	12.8 [6.7–17.4]	0.0053
	CD16+ mDCs	95.8 [88.5–97.5]	98.1 [96.7–98.7]	0.0034
	CD141+ mDCs	7.6 [0.0–22.3]	5.9 [2.6–13.6]	0.9075
	pDCs	0.3 [0.0–0.9]	1.4 [0.4–2.2]	0.0024
CD4	mDCs	8.8 [2.5–24.1]	5.6 [4.0–10.6]	0.3229
	CD1c+ mDCs	27.0 [7.7–61.5]	23.0 [15.7–51.1]	0.6457
	CD16+ mDCs	8.5 [2.2–16.5]	10.7 [6.6–14.6]	0.3194
	CD141+ mDCs	21.3 [10.6–51.1]	40.0 [21.1–47.7]	0.1109
	pDCs	57.3 [46.6–77.9]	70.5 [59.0–87.9]	0.0750
IDO	mDCs	1.3 [0.8–3.1]	2.0 [1.5–2.8]	0.1469
	CD1c+ mDCs	9.1 [2.4–23.2]	2.2 [1.6–4.5]	0.0039
	CD16+ mDCs	6.8 [0.1–27.2]	0.4 [0.0–0.7]	0.0004
	CD141+ mDCs	72.1 [56.9–85.7]	69.2 [59.4–79.5]	0.6460
	pDCs	0.0 [0.0–0.1]	0.1 [0.0–0.3]	0.2071
PD-L1	mDCs	17.4 [5.1–34.4]	21.8 [10.1–41.3]	0.2531
	CD1c+ mDCs	0.9 [0.4–5.2]	0.6 [0.2–1.7]	0.1810
	CD16+ mDCs	28.6 [13.8–47.9]	21.0 [6.1–41.0]	0.2107
	CD141+ mDCs	0.0 [0.0–2.0]	0.9 [0.0–2.7]	0.2166
	pDCs	0.8 [0.2–2.1]	5.6 [3.1–8.7]	<0.0001

Percentages of dendritic cells positive for activation markers in acute SARS-CoV-2 infected patients (Acute) and healthy donors (HD) are presented. The median with interquartile ranges [IQR] is shown. Significant differences are indicated in bold